Abstract:Key PointsHigh-mobility group box 1 protein (HMGB1) is a highly conserved nuclear protein that has a surprising extracellular role. Not only does it bind DNA, increasing access to transcription factors, but it also recruits cells across endothelial barriers and promotes the local production of tumour-necrosis factor (TNF), interleukin-6 (IL-6) and interferon-γ.HMGB1 is released from necrotic cells and is secreted by activated macrophages, natural killer cells and mature dendritic cells, but it is not produced by neutrophils. HMGB1 is a 'leaderless' cytokine, requiring specialized means to gain access to the immunological synapse or to be secreted.By contrast, after DNA damage as a result of apoptotic cell death, ultraviolet-light irradiation or platination, HMGB1 is sequestered in the nucleus.During sepsis, HMGB1 release occurs considerably later than macrophage secretion of the classical early pro-inflammatory mediators TNF and IL-1.Receptors for HMGB1 include RAGE (receptor for advanced glycation end-products), Toll-like receptor 2 (TLR2) and TLR4, and possibly other as-yet-unknown receptors.RAGE is encoded in the MHC class III region and is expressed as both a transmembrane molecule — which directly interacts with extracellular-signal-regulated kinase 1 (ERK1) and/or ERK2 and drives activation of the mitogen-activated protein kinase p38 and nuclear factor-κB — and as a soluble molecule. Soluble RAGE blocks RAGE ligands, including HMGB1 and S100 proteins.The expression of RAGE by activated endothelia promotes leukocyte recruitment, through the interaction of RAGE with myeloid cells that express the β2-integrin MAC1, and this is augmented in the presence of S100 proteins. Macrophages also express HMGB1 at the cell surface when they are activated, facilitating their recruitment through interaction with RAGE expressed by endothelial cells and enabling their translocation across endothelial barriers.Controlling HMGB1 activity and release is an approach that is being developed as an experimental therapy for patients with sepsis, arthritis, cancer and other disorders.

Pathophysiological Function of HMGB1 As a Late- Acting Mediator of Inflammation

HMGB1, a potent proinflammatory cytokine in sepsis.

HMGB1 as a DNA-binding cytokine

[The Extracellular Role of High Mobility Group Box-1 Protein in Regulation of Immune Response].

Deficiency of the Novel High Mobility Group Protein HMGXB4 Protects Against Systemic Inflammation-Induced Endotoxemia in Mice.

High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal

Targeting HMGB1 for the treatment of sepsis and sepsis-induced organ injury

Novel Insights For High Mobility Group Box 1 Protein-Mediated Cellular Immune Response In Sepsis: A Systemic Review

HMGB1 as a therapeutic target in disease

Therapeutic Potential of HMGB1-targeting Agents in Sepsis.

Relationship of high mobility group boxl and inflammation

[Advances in high mobility group box-1 protein mediated multiple organ dysfunction and its potential interventional strategies].

The Regulatory Role of High-Mobility Group Protein 1 in Sepsis-Related Immunity

Research Progress of Extracellular HMGB1

The mechanism of HMGB1 secretion and release

Relationship Between High Mobility Group Box- 1 Protein and Inflammation

Targeting Inflammation Driven by HMGB1

The Effect and Regulatory Mechanism of High Mobility Group Box-1 Protein on Immune Cells in Inflammatory Diseases

Extracellular Roles of High-Mobility-group B1

[Role of HMGB1 in Inflammatory-mediated Injury Caused by Digestive System Diseases and Its Repair].

HMGB1: An overview of its roles in the pathogenesis of liver disease